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Background: CMV infection resistant or refractory to the
standard antiviral therapy constitutes a major threat to
immunocompromised patients, especially leukemia or he-
matopoietic stem cell transplant (HSCT) patients. In addition,
treatment of CMV recurrences may lead tomyelosuppression
or renal insufﬁciency due to adverse effects of ganciclovir
derivatives or foscarnet. Leﬂunomide, a drug originally
approved for rheumatoid arthritis, has been reported to have
anti-CMV activity. We report our experience with leﬂuno-
mide therapy in patients with recalcitrant CMV infection.
Methods: A Single center, retrospective study of 4 patients
following HSCT and 1 patient with leukemia. Clinical data
were extracted from the electronic medical record. CMV
antigenemia (CMV-Ag) was performed for diagnosis of CMV
reactivation.
Results: After genotypic analysis, 2 isolates had UL97 and
UL54mutations,1 had UL97,1 showed nomutations, and in 1
isolate, genotyping was not performed. Interestingly, 4 of 5
patients had no end-organ diseases, while 1 had CMV
pneumonitis. Leﬂunomide was used in combination with
ganciclovir derivatives or foscarnet in 4 patients, while it was
used alone in 1. Leﬂunomide at an average dose of 30mg/day
was initiated at mean CMV Ag of 2078 cells (range: 194-
6888) and serum level was around 30 mcg/mL in most of the
patients. Complete clearance of CMV Ag was observed in 4
patients and the mean duration from start of leﬂunomide to
clearance was 40 days (26-73 d) and no one progressed to
end-organ disease. The remaining patient with CMV pneu-
monitis expired with respiratory failure before CMV Ag was
cleared, however, CMV Ag dropped from 2592 to 47 cells at
36 days after initiation of leﬂunomide. No adverse events
related to leﬂunomide use were observed.
Conclusion: Leﬂunomide, alone or in combination with
ganciclovir derivatives or foscarnet, could be a useful alter-
native therapy of resistant or refractory CMV reactivation
although time to response is prolonged. Its usefulness in
patients with end-organ disease still needs to be determined.373
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Background: Allo SCT can be curative in patients with he-
matologic malignancies. However, its utilization in the
elderly population has been limited because of concerns of
mortality associated with it.
Methods: We retrospectively analyzed the outcomes of all
patients over age 70 years who underwent Allo- SCT at
UMass Medical Center since 2010.
Results: 18 patients (12 males; 6 females) were identiﬁed
from the database. Median age was 72.5 years (range 70 e
84). Six (33%) were over age 75 years. Median hematopoietic
stem cell transplant co-morbidity index was 4 (range 0 - 9).
Diagnoses were acute myeloid leukemia (n¼10), myelodys-
plastic/myeloproliferative syndromes/ (n¼7), chronic
lymphoblastic leukemia (n¼1). Eight (44%) of the patients
had persistent disease at the time of transplant. Median time
from diagnosis to transplant was 208.5 days (77.0 e 3959.0).
All patients received stem cells from an unrelated donor with
the source being peripheral blood (n¼14), cord blood (CB)
(n¼3) and bone marrow (n¼1). Preparative regimens were
reduced intensity (RIC) (n¼17) and ablative (n¼1). CB
transplant regimen consisted of Thiotepa (5-10 mg/kg), Flu-
darabine (Flu), and Melphalan (100-140mg/kg). RIC regimen
included Flu, and Busulfan (Bu) (3.2mg/kg x2). One patient
received myeloablative regimen: Flu and Bu (3.2mg/kg x 3).
HLA match was 4/6 for CB recipients and 10/10 for unrelated
donor recipients. Graft-versus-host disease (GvHD) prophy-
laxis was calcineurin inhibitor/mycophenolate mofetil
(MMF) (n¼15); Sirolimus /MMF) (n¼2) and Sirolimus with
post transplant cyclophosphamide (n¼1). Seventeen (94%)
patients also received peri-transplant antithymocyte glob-
ulin. Median CD34 dose infused was 5.0x10e6/kg (range
0.03 e 6.00). Median time to neutrophil engraftment was 17
days (range 13 e 30). Median time to platelet engraftment
was 15 days (range 0 e 56). Median length of hospitalization
was 19.5 days (range 13 e 49). The 100-day and 1-year non-
relapse mortality (NRM) were 16.7% (CI 4.4 e 51.8%) and
35.2% (CI 14.9 e 69.0%) respectively. Cumulative incidence of
acute GvHD at day 100 was 36.4%. For patients surviving
beyond 6 months (n¼ 9), cumulative incidence of chronic
GvHD was 44.4%. There was no acute or chronic GvHD in
the three CB transplant recipients. Median follow-up of
surviving patients was 477.0 days (21 e 1288). Kaplan Meier
estimate of one and two year overall survival rate was 54.2%
(CI 25.0-76.2%).
Conclusion: Allo-SCT can be safely performed in selected
patients over age 70.
